Wu Yuling, Pan Nana, An Yi, Xu Mengyuan, Tan Lijuan, Zhang Lijuan
Systems Biology & Medicine Center for Complex Diseases, Center for Clinical Research, Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China.
Front Cardiovasc Med. 2021 Feb 3;7:617277. doi: 10.3389/fcvm.2020.617277. eCollection 2020.
The incidence of myocardial infarction (MI) increases every year worldwide. Better diagnostic and prognostic biomarkers for clinical applications are the consistent pursuit of MI research. In addition to electrocardiogram, echocardiography, coronary angiography, etc., circulating biomarkers are essential for the diagnosis, prognosis, and treatment effect monitoring of MI patients. In this review, we assessed both strength and weakness of MI circulating biomarkers including: (1) originated from damaged myocardial tissues including current golden standard cardiac troponin, (2) released from non-myocardial tissues due to MI-induced systems reactions, and (3) preexisted in blood circulation before the occurrence of MI event. We also summarized newly reported MI biomarkers. We proposed that the biomarkers preexisting in blood circulation before MI incidents should be emphasized in research and development for MI prevention in near future.
全球范围内,心肌梗死(MI)的发病率逐年上升。开发更适用于临床的诊断和预后生物标志物一直是心肌梗死研究的目标。除了心电图、超声心动图、冠状动脉造影等检查外,循环生物标志物对于心肌梗死患者的诊断、预后评估及治疗效果监测至关重要。在本综述中,我们评估了心肌梗死循环生物标志物的优缺点,包括:(1)源自受损心肌组织的生物标志物,如当前的金标准心肌肌钙蛋白;(2)因心肌梗死引发的全身反应而从非心肌组织释放的生物标志物;(3)在心肌梗死事件发生前就已存在于血液循环中的生物标志物。我们还总结了新报道的心肌梗死生物标志物。我们建议,在不久的将来,应重视对心肌梗死事件发生前就已存在于血液循环中的生物标志物的研发,以预防心肌梗死。